These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 5854414)

  • 1. The treatment of experimental mouse hemoblastosis. 3. Chemotherapy of the LaH VUFB leukemia with some 4-amino analogues of folic acid.
    Soucek J; Sochman J; Motycka K; Novotná O; Slavík K
    Neoplasma; 1965; 12(4):425-33. PubMed ID: 5854414
    [No Abstract]   [Full Text] [Related]  

  • 2. Studies on the effect of antifolics in mouse leukemia.
    Motycka K
    Natl Cancer Inst Monogr; 1971 Dec; 34():167-77. PubMed ID: 4110901
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of experimental mouse hemoblastosis. VII. Time course of change in the frequency of mitoses of leukaemic leukocytes (L 14 AKR and LaH VUFB) after administration of methotrexate.
    Motycka K; Stránská E; Andrysek O; Coufalová H; Jehlicková M
    Neoplasma; 1970; 17(2):137-42. PubMed ID: 5425391
    [No Abstract]   [Full Text] [Related]  

  • 4. [The biological and therapeutic value of 4-aminopteroylaminoadipic acid].
    Trufanov AV; Dzhelieva ZN
    Vopr Med Khim; 1972; 18(4):418-21. PubMed ID: 4196602
    [No Abstract]   [Full Text] [Related]  

  • 5. [New route of regulating folic acid metabolism in experimental chemotherapy of leukoses and malignant neoplasms].
    Bukin IuV; Sergeev AV; Raushenbakh MO
    Vestn Akad Med Nauk SSSR; 1971; 26(3):49-55. PubMed ID: 4326180
    [No Abstract]   [Full Text] [Related]  

  • 6. [Comparative study of the characteristics and activity of tetrahydrofolate dehydrogenases of rat liver and spleen in leukemias of viral etiology].
    Sergeev AV
    Vopr Med Khim; 1968; 14(6):606-11. PubMed ID: 5733701
    [No Abstract]   [Full Text] [Related]  

  • 7. The association of increased dihydrofolate reductase with amethopterin resistance in mouse leukemia.
    FRIEDKIN M; CRAWFORD E; HUMPHREYS SR; GOLDIN A
    Cancer Res; 1962 Jun; 22():600-6. PubMed ID: 13895219
    [No Abstract]   [Full Text] [Related]  

  • 8. The treatment of experimental mouse hemoblastosis. VI.
    Pristoupilová K; Soucek J; Motycka K; Slavík K
    Neoplasma; 1968; 15(1):77-87. PubMed ID: 5689889
    [No Abstract]   [Full Text] [Related]  

  • 9. THE TREATMENT OF EXPERIMENTAL MOUSE HEMOBLASTOSIS. II. THE EFFECT OF LONG-TERM ADMINISTRATION OF SOME FOLIC ACID ANTAGONISTS ON MICE OF THE AKR STRAIN.
    MOTYCKA K; SOUCEK J; SLAVIK K
    Neoplasma; 1964; 11():399-408. PubMed ID: 14200028
    [No Abstract]   [Full Text] [Related]  

  • 10. Increased levels of folic acid reductase as a mechanism of resistance to amethopterin in leukemic cells.
    FISCHER GA
    Biochem Pharmacol; 1961 Jul; 7():75-7. PubMed ID: 13699838
    [No Abstract]   [Full Text] [Related]  

  • 11. Nonclassical 2,4-diamino-8-deazafolate analogues as inhibitors of dihydrofolate reductases from rat liver, Pneumocystis carinii, and Toxoplasma gondii.
    Gangjee A; Zhu Y; Queener SF; Francom P; Broom AD
    J Med Chem; 1996 Apr; 39(9):1836-45. PubMed ID: 8627607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of dihydrofolate reductase inhibitors encompassing a bridging ester group. Evaluation in a mouse colitis model.
    Graffner-Nordberg M; Fyfe M; Brattsand R; Mellgård B; Hallberg A
    J Med Chem; 2003 Jul; 46(16):3455-62. PubMed ID: 12877583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irreversible enzyme inhibitors. 133. Studies on differential irreversible inhibition of dihydrofolic reductase from three strains of L1210 leukemia, liver, spleen, and intestine of the mouse.
    Baker BR; Lourens GJ; Meyer RB; Vermeulen NM
    J Med Chem; 1969 Jan; 12(1):67-73. PubMed ID: 5763043
    [No Abstract]   [Full Text] [Related]  

  • 14. Conference on obstacles to the control of acute leukemia. Limitations on the therapeutic effectiveness of the folic acid antagonists.
    Werkheiser WC
    Cancer Res; 1965 Oct; 25(9):1608-13. PubMed ID: 5323970
    [No Abstract]   [Full Text] [Related]  

  • 15. Biochemical pharmacology of lipophilic diaminopyrimidine antifolates in mouse and human cells in vitro.
    Greco WR; Hakala MT
    Mol Pharmacol; 1980 Nov; 18(3):521-8. PubMed ID: 6970329
    [No Abstract]   [Full Text] [Related]  

  • 16. [Lysosomal hydrolase activity during development of experimental leukemia].
    Drozhennikov VA; Perevezentseva OS
    Biull Eksp Biol Med; 1980 Jun; 89(6):715-6. PubMed ID: 7397362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incorporation of formate-C-14 in normal and leukemic mice during extended treatment with amethopterin and 3',5'-dichloramethopterin.
    SCHRECKER AW; MEAD JA; GOLDIN A
    Cancer Res; 1962 Jan; 22():15-20. PubMed ID: 13909245
    [No Abstract]   [Full Text] [Related]  

  • 18. 2,4-diamino-5-deaza-6-substituted pyrido[2,3-d]pyrimidine antifolates as potent and selective nonclassical inhibitors of dihydrofolate reductases.
    Gangjee A; Vasudevan A; Queener SF; Kisliuk RL
    J Med Chem; 1996 Mar; 39(7):1438-46. PubMed ID: 8691474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Empirical vs. rational approaches in cancer chemotherapy.
    Friedkin M; Crawford EJ; Plante LT
    Ann N Y Acad Sci; 1971 Nov; 186():209-13. PubMed ID: 5002298
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of A-methopterin on nucleic acid synthesis in leukemia spleen breis.
    BALIS ME; DANCIS J
    Cancer Res; 1955 Oct; 15(9):603-8. PubMed ID: 13261082
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.